NanoLogix Launches New Family Of “Quick-Tests�Designed To Identify Bacteria 3 to 4 Times Faster Than Traditional Technology

Quick-Tests Detect and Identify Live-Cell bacteria with improved accuracy and speed. E.coli, Salmonella and Listeria Quick-Tests first to be marketed

HUBBARD, OH, October 12, 2010-- NanoLogix, Inc. (PINKSHEETS: NNLX) announces its new Quick-Test product line for detection and identification of aerobic live-cell bacteria. With the NanoLogix Quick-Tests, the research community will be able to obtain high-sensitivity analysis results in reduced time with lower costs than traditional technologies. The new NanoLogix Quick Test product line complements the Company’s existing BNP and BNF membrane and filtration technologies with a projected market of medical laboratories, food and beverage producers, pharmaceutical, university and other institutional users.

The NanoLogix Quick-Tests detect and identify a multitude of live-cell bacteria, such as E.coli, Salmonella, and Listeria, with the additional capability of rapid identification of yeasts. These results can be obtained in as little as a quarter of the time of conventional methods, in concentrations potentially as small as a single cell.

Dr. Sergey Gazenko, developer of BNC, BNP, and BNF technologies stated “We’ve taken our current, peer-reviewed technology and developed the Quick-Test technology to assist in reducing the time required in sample analysis and subsequent diagnosis�

“With infectious diseases being the second leading cause of death worldwide, the demand for fast, inexpensive and simple testing methods that do not require specialized equipment or complex training is growing. To assist in satisfying that demand, NanoLogix's Quick-Tests were developed to provide the ability to obtain rapid analysis results without large capital expenditures and increased burdens on existing staff� said Bret Barnhizer, NanoLogix CEO.

Each Quick-Test kit is designed to provide results for fifty individual tests of the targeted bacteria and each test kit is identified by the name of that specific bacteria, e.g., E.coli Quick-Test , Salmonella Quick-Test, etc. NanoLogix currently has Quick Tests available for E.coli, Salmonella, and Listeria with additional bacteria Quick-Tests available upon request.

For more information please visit www.nanologix.com.

Update On NanoLogix and US EPA CRADA

The Cooperative Research and Development Agreement recently signed between NanoLogix and the United States Environmental Protection Agency with the goal of improving comprehensive water quality testing runs through 2012. For more details pertaining to the NanoLogix CRADA with the EPA, please visit: http://www.epa.gov/microbes/mceardnewsarchive.html.

About NanoLogix, Inc.

NanoLogix is a biotechnology company focused primarily on medical diagnostics. Its products offer accelerated detection and identification of microorganisms present in a multitude of infectious and non-infectious human diseases, including but not limited to tuberculosis, non-tuberculous mycobacterium (NTM), pneumonia, anthrax, and plague. In addition to medical and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing.

Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, antibiotic sensitivity, stem-cell research, and bioreactor-based hydrogen generation. For more information visit www.nanologix.com.

________________________________________

Media Contact:
Lisa Ann Pinkerton
Telephone: 650-288-1824
E-mail: lisaann@technicacommunications.com

Investor Contact:
Carol Surrena
NanoLogix, Inc.
Telephone: 330-534-0800
E-mail: carol@nanologix.com

This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

Copyright 2011 NanoLogix, Inc All Rights Reserved